AzurRx BioPharma (NASDAQ: AZRX) is one of 103 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare AzurRx BioPharma to related companies based on the strength of its earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations.
Risk and Volatility
AzurRx BioPharma has a beta of -1.83, meaning that its stock price is 283% less volatile than the S&P 500. Comparatively, AzurRx BioPharma’s rivals have a beta of 0.85, meaning that their average stock price is 15% less volatile than the S&P 500.
This table compares AzurRx BioPharma and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|AzurRx BioPharma||N/A||-$14.59 million||N/A|
|AzurRx BioPharma Competitors||$8.31 billion||$1.11 billion||152.95|
AzurRx BioPharma’s rivals have higher revenue and earnings than AzurRx BioPharma.
This table compares AzurRx BioPharma and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|AzurRx BioPharma Competitors||-2,466.98%||-68.60%||-7.96%|
Institutional and Insider Ownership
8.2% of AzurRx BioPharma shares are held by institutional investors. Comparatively, 43.9% of shares of all “Pharmaceuticals” companies are held by institutional investors. 9.1% of AzurRx BioPharma shares are held by company insiders. Comparatively, 11.3% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This is a breakdown of current recommendations and price targets for AzurRx BioPharma and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|AzurRx BioPharma Competitors||959||3858||6884||183||2.53|
AzurRx BioPharma presently has a consensus target price of $8.00, indicating a potential upside of 128.57%. As a group, “Pharmaceuticals” companies have a potential upside of 18.87%. Given AzurRx BioPharma’s stronger consensus rating and higher probable upside, equities research analysts clearly believe AzurRx BioPharma is more favorable than its rivals.
AzurRx BioPharma rivals beat AzurRx BioPharma on 8 of the 12 factors compared.
About AzurRx BioPharma
AzurRx BioPharma, Inc. is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company’s product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant deoxyribonucleic acid (DNA) technology for the treatment of exocrine pancreatic insufficiency (EPI), associated with chronic pancreatitis (CP) and cystic fibrosis (CF). AZX1101 is a recombinant-lactamase combination of bacterial origin under development for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics (known as nosocomial infections), as well as the prevention of antibiotic-associated diarrhea (AAD).
Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.